Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –MELBOURNE, Australia and SAN ...
Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company ...
H. Lundbeck A/S (Lundbeck) today announced that pipeline developments regarding amlenetug, a novel investigational molecule for the potential treatment of Multiple System Atrophy (MSA), will be ...
Research Triangle Park, North Carolina Friday, September 19, 2025, 10:00 Hrs [IST] ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
23d
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
The US Food and Drug Administration (FDA) has granted approval for Tiziana Life Sciences’ investigational new drug (IND) to advance its Phase IIa study of intranasal foralumab intended to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback